Benzodiazepine Discontinuation Difficulties in Panic Disorder: Conceptual Model and Outcome for Cognitive-Behavior Therapy

Authors: Otto, M.W.; Hong, J.J.; Safren, S.A.

Source: Current Pharmaceutical Design, Volume 8, Number 1, 1 January 2002 , pp. 75-80(6)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

There is consistent support for the efficacy of cognitive-behavior therapy (CBT) to aid the successful discontinuation of benzodiazepine (BZ) medication in patients with panic disorder, and help these individuals maintain treatment gains while off medication. In this article, we provide a conceptual model for BZ discontinuation difficulties in patients with panic disorder. Outcome studies are reviewed, and are placed in the context of other evidence for the efficacy of CBT in patients with this disorder.

Keywords: Cognitive-Behavior

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612023396726

Publication date: 2002-01-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.